ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: The use of tyrosine kinase inhibitors (TKIs) targeting the BCR::ABL1 kinase [2] has transformed CML into a manageable disease, with patients having a life expectancy comparable to that of the healthy population [3].